Ingestible biosensors market seen reaching $3.23 billion by 2030

The Business Research Company says the ingestible biosensors market is set to grow from $1.97 billion in 2025 to $3.23 billion by 2030, driven by demand for non-invasive diagnostics and real-time health monitoring. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Ingestible biosensors could reduce reliance on invasive procedures by giving clinicians real-time data from inside the gastrointestinal tract. - The market’s projected growth suggests stronger adoption of capsule-based diagnostics, mobile health integration and remote monitoring. - The shift matters for patients with gastrointestinal disorders, older adults and providers looking for earlier detection and more personalized care.

What happened: - The Business Research Company projected the ingestible biosensors market at $2.18 billion in 2026, up from $1.97 billion in 2025. - The firm forecast the market will reach $3.23 billion by 2030, implying a 10.3% compound annual growth rate through the end of the decade. - The report highlighted North America as the largest regional market in 2025. - The report identified Asia-Pacific as the fastest-growing region in the outlook period. - Download a free sample of the report.

The details: - Ingestible biosensors are medical devices designed to be swallowed safely and move through the gastrointestinal tract. - The devices measure pH, temperature, pressure and specific biomarkers. - The sensors transmit data to external devices for ongoing monitoring. - The technology is positioned for gastrointestinal health tracking, abnormality detection and treatment adjustment. - The market’s recent growth was tied to limits in traditional endoscopy, demand for non-invasive diagnostics, miniaturized sensor advances, higher gastrointestinal disease incidence and early capsule endoscopy adoption. - The report pointed to future growth drivers including personalized medicine, mobile health platforms, an aging global population, better data transmission and wider clinical adoption. - Expected trends include non-invasive gastrointestinal monitoring, smart capsule diagnostics, real-time internal health tracking, personalized digestive health assessments and minimally invasive diagnostic alternatives. - The report said real-time monitoring is a major demand driver because it enables continuous collection, analysis and transmission of health data. - A HealthArc report from October 2024 said about 30 million U.S. patients were using remote patient monitoring, with that number expected to reach 70.6 million by the end of 2025. - HealthArc also said 42 states now include RPM in Medicaid coverage, and more than 26% of Americans are expected to adopt these technologies. - View the full report.

Between the lines: - The forecast points to a broader move toward diagnostics that are less invasive, more continuous and easier to integrate into digital care systems. - The strongest demand case appears to be not just better sensing, but better connectivity between internal monitoring devices and remote care workflows. - North America’s lead suggests the market is benefiting from early infrastructure and adoption, while faster growth in Asia-Pacific signals expanding global demand.

What’s next: - The market is expected to keep expanding through 2030 as clinical use broadens and data transmission improves. - The company’s 2026 report edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics and updated trend analysis. - Broader adoption will likely depend on how quickly clinicians and health systems incorporate ingestible biosensors into routine digestive and remote monitoring care.

The bottom line: - Ingestible biosensors are moving from niche diagnostics toward a faster-growing market with a clear case for non-invasive, real-time patient monitoring.